Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants
NCT06895993Phase 1Completed
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Maximum Observed Serum Concentration of Total Iron, Area Under the Serum Concentration-Time Curve of Total Iron and 2 more. Started Apr 2025; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06895993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895993.